The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Deutsche Boerse AG
OTC:DBOEF
|
DE |
|
Zoominfo Technologies Inc
F:ZOM
|
US |
|
Lamar Advertising Co
NASDAQ:LAMR
|
US |
|
NRJ Group SA
F:NR8
|
FR |
|
D
|
Del Monte Corp
F:FDM
|
KY |
|
Akron PAO
MOEX:AKRN
|
RU |
|
G
|
Gesco SE
XMUN:GSC1
|
DE |
|
Innate Pharma SA
PAR:IPH
|
FR |
|
A
|
Amgen Inc
XMUN:AMG
|
US |
|
A2A SpA
MIL:A2A
|
IT |
|
Gersan Elektrik Ticaret ve Sanayi AS
OTC:GERLF
|
TR |
|
Covalon Technologies Ltd
XTSX:COV
|
CA |
|
F
|
Fortune Real Estate Investment Trust
OTC:FRIVF
|
HK |
|
Marubeni Corp
TSE:8002
|
JP |
|
Q
|
Quanta Services Inc
SWB:QAA
|
US |
|
B
|
BoKwang Industry Co Ltd
KOSDAQ:225530
|
KR |
|
N
|
Nebius Group NV
DUS:YDX
|
NL |
|
Wealth Minerals Ltd
XTSX:WML
|
CA |
|
Unite Group PLC
LSE:UTG
|
UK |
|
M
|
Marathon Digital Holdings Inc
F:M44
|
US |
|
M
|
MC Mining Ltd
XMUN:G1V
|
AU |
|
L
|
Likewise Group PLC
F:7RL
|
UK |
|
ICU Medical Inc
NASDAQ:ICUI
|
US |
|
I
|
International Graphite Ltd
ASX:IG6
|
AU |
Deutsche Boerse AG (DBOEF)’s 12-month stock price forecast through October 2027 has a consensus target of $355.76, broadly in line with the current price. The forecast is based on price targets from 22 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
DBOEF is 355.76 USD with a low forecast of 289.16 USD and a high forecast of 406.78 USD.
Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 5 years is 3%.
Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 3 years is 6%.
Over the last 13 years, the compound annual growth rate for Operating Income has been 9%. The projected CAGR for the next 8 years is 3%.
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 11%.
Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 5 years is 10%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more